[PDF] Top 20 La Educación Universitaria Para La Sostenibilidad Arquitectónica. Caso Ecuador

... can be more severe than major ABO-mismatched HSCT that usually decreases after 5-10 days. In this situation, direct antiglobulin test (DAT) is usually positive against recipient’s erythrocytes antigens. A second ... See full document

... of ABO mismatch on outcomes such as OS, RFS, and NRM, time to engraftment, relapse and also ...minor blood group mismatched ...minor blood group mismatched ...minor ABO-mismatched ... See full document

... for Blood and Marrow Transplantation (EBMT), the Chi- nese Hematopoietic Stem Cell Transplantation Associa- tion must make considerable progress in establishing itself as a ... See full document

... in clinical blood cultures in only one episode and in the remaining three documented BSIs the identified bacteria isolated by surveillance cultures was not the same as the bacteria identified by ... See full document

... Regarding blood glucose monitoring, all institutes mo- nitor glucose level ...get blood glucose ...a clinical trial to assess the beneficial effect of ... See full document

... Haematopoietic stem cell transplantation (HSCT) has progressed rapidly since its introduction about five decades ...Peripheral blood has largely replaced bone marrow as the preferred source of ... See full document

... CMV DNA in blood specimens was detected by nested- PCR using primers, as described by Demmler et al . [12] and Shibata et al . [13]. CMV DNA was extracted from peripheral blood by a manual phenol-chloroform ... See full document

... Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma* Ana I.. Porr[r] ... See full document

... after stem cell transplantation were, on average, more likely to die over the next 3 years than those with high gut microbial diversity, independent of other known mortality predictors in allo-HSCT, ... See full document

... Allogeneic hematopoietic stem cell transplantation is mainly indicated in bone marrow dysfunction related to blood diseases, but also in some rare diseases (adrenoleucodystrophy, ... See full document

... In blastocyst complementation, ESCs/iPSCs are injected into the blastocysts, which are embryonic structures formed after fertilization. Injected ESCs/iPSCs synchronize with the development of the host embryo to generate ... See full document

... Additional file 2: Figure S1. Stacked bar graphs summarizing genes at or near integration sites in each sample studied here. Integration site abundance was determined using the SonicAbundance method. The most abundant ... See full document

... T cell–mediated and natural ...remission. Hematopoietic stem cell transplantation (HSCT), however, is the only curative option, but optimal modalities and long-term outcome are not yet ... See full document

... As clinical outcomes in HIV-infected patients who received autol- ogous HSCT improved, interest grew in genetically modifying stem cells to render them resistant to HIV-1 ... See full document

... developing cell-based therapy such as GlaxoSmithKline, Johnson & Johnson, Pfizer, and Sanofi (Genzyme) ...of cell-based therapy research and development (R&D) industrial players in stock market ... See full document

... burden as much as possible and at the same time not to use a high dose that affects the reestablishment of the immune system and a functioning BM. Optimization of the ‘magic dose’ to achieve an ideal balanced treatment ... See full document

... Allogeneic HSCT has been shown to cure patients with FL. Allogeneic transplants should be offered to patients who are young, have a matched donor, and are beyond first CR. Myeloablative regimens are associated with ... See full document

... As previously discussed, donor availability still remains one of the major limiting factors in offering this modality to more individuals. As SCD is a disease which primarily affects those of African or Hispanic descent ... See full document

... for hematopoietic stem cell transplantation, including 53 males and 48 females with a mean age of 32 years (range from 18 to 43 ...collected cell clus- ters were used immediately or ... See full document

... that stem cell ther- apy would surpass the conventional synthetic drug ther- apy, which is the only treatment modality currently available for many ...can stem cells themselves can be considered as a ... See full document